Fatal Anaphylaxis: Mortality Rate and Risk Factors

September–October, 2017 Volume 5, Issue 5, Pages 1169–1178

Paul J. Turner, MD, PhD

, 

Elina Jerschow, MD

, 

Thisanayagam Umasunthar, MD

, 

Robert Lin, MD

, 

Dianne E. Campbell, MD, PhD

, 

Robert J. Boyle, MB, ChB, PhDCorrespondence information about the author MB, ChB, PhD Robert J. BoyleEmail the author MB, ChB, PhD Robert J. Boyle

Open Access

PlumX Metrics

DOI: http://dx.doi.org/10.1016/j.jaip.2017.06.031

 |

Article Info

• Abstract

• Full Text
• Images
• References

Up to 5% of the US population has suffered anaphylaxis. Fatal outcome is rare, such that even for people with known venom or food allergy, fatal anaphylaxis constitutes less than 1% of total mortality risk. The incidence of fatal anaphylaxis has not increased in line with hospital admissions for anaphylaxis. Fatal drug anaphylaxis may be increasing, but rates of fatal anaphylaxis to venom and food are stable.

Multicenter prevalence of anaphylaxis in clinic-based oral food challenges

Kwei Akuete, MD, MPH

, 

Danielle Guffey, MS

, 

Ryan B. Israelsen, MD

, 

John M. Broyles, MS, CRNP

, 

Lori Jo Higgins, LPN

, 

Todd D. Green, MD

, 

David R. Naimi, DO

, 

Andrew J. MacGinnitie, MD, PhD

, 

Girish Vitalpur, MD

, 

Charles G. Minard, PhD

, 

Carla M. Davis, MDCorrespondence information about the author MD Carla M. DavisEmail the author MD Carla M. Davis

Open Access

PlumX Metrics

DOI: http://dx.doi.org/10.1016/j.anai.2017.07.028

 |

Article Info

• Abstract

• Full Text

• Images
• References

Article Outline

1. Introduction
2. Methods
3. Results
4. Discussion
5. Supplementary Data
6. References

Abstract

Jump to SectionIntroductionMethodsResultsDiscussionSupplementary DataReferences

Background

Although previous single-center studies report the rate of anaphylaxis for oral food challenges (OFCs) as 9% to 11%, little is known regarding the epidemiology of clinical OFCs across multiple centers in the United States.

Passive blood anaphylaxis: subcutaneous immunoglobulins are a cause of ongoing passive anaphylactic reaction

Allergy, Asthma & Clinical Immunology

Allergy, Asthma & Clinical Immunology 2017 13:41

https://doi.org/10.1186/s13223-017-0213-x

Przemyslaw Zdziarski, Andrzej Gamian, Jacek Majda and Agnieszka Korzeniowska-Kowal

Abstract
Background
Allergic, especially anaphylactic, reactions during immunoglobulin replacement therapy are rare, but their pathophysiology and classification remain ambiguous. Recent findings show positive results of skin tests with commercially available immunoglobulins, but target antigens and responsible compounds of the tested immunoglobulins have not been strictly identified.

Sublingual immunotherapy (SLIT) for house dust mites does not prevent new allergen sensitization and bronchial hyper-responsiveness in allergic rhinitis children

PloS One 2017, 12 (8): e0182295

Jae Hyun Lim, Jin Youp Kim, Doo Hee Han, Chul Hee Lee, Seung-No Hong, Jee Hye Wee, Sue K Park, Chae-Seo Rhe

INTRODUCTION: The aim of this study is to identify the effects of sublingual immunotherapy (SLIT) on immunologic parameters and bronchial-hyper-responsiveness in children with allergic rhinitis to house-dust mite (HDM), through long-term follow-up cohort.

Comparison of the Performance of Skin Prick, ImmunoCAP, and ISAC Tests in the Diagnosis of Patients with Allergy

Int Arch Allergy Immunol 2017;172:215-223

https://doi.org/10.1159/00046432

Griffiths R.L.M. · El-Shanawany T. · Jolles S.R.A. · Selwood C. · Heaps A.G. · Carne E.M. · Williams P.E. 

Abstract

Background: Allergy is diagnosed from typical symptoms, and tests are performed to incriminate the suspected precipitant. Skin prick tests (SPTs) are commonly performed, inexpensive, and give immediate results. Laboratory tests (ImmunoCAP) for serum allergen-specific IgE antibodies are usually performed more selectively. The immuno-solid phase allergen chip (ISAC) enables testing for specific IgE against multiple allergen components in a multiplex assay.

Dr. Robbie Pesek Discusses Food allergy diagnosis and management

Dr. Robbie Pesek Discusses Food allergy diagnosis and management.

ACAAICOLA

Dr. Phil Lieberman discusses the diagnosis and management anaphylaxis

Dr. Phil Lieberman discusses the diagnosis and management anaphylaxis

ACAAICOLA

The impact of 10-valent and 13-valent pneumococcal conjugate vaccines on hospitalization for pneumonia in children: A systematic review and meta-analysis

Vaccine

Available online 11 September 2017

In Press, Corrected Proof

Review

Author links open overlay panelCristiano Alicino ChiaraPaganinoAndrea Orsi Matteo Astengo CeciliaTrucchi Giancarlo Icardi Filippo Ansaldi

https://doi.org/10.1016/j.vaccine.2017.09.005Get rights and content

Under a Creative Commons license

open access

Highlights
• Since 2010, PCV10 and PCV13 became available for use in children. 

• This meta-analysis assessed the impact PCV10 and PCV13 in pneumonia hospitalization among children. 

• Novel PCVs reduced hospitalization for pneumonia in children 

• Reduction was more pronounced for radiologically confirmed pneumonia with respect to clinically confirmed pneumonia. 

• None of the studies included in this meta-analysis had been designed to directly compare the impact of PCV10 and PCV13.